October 26, 2021 10:23 AM EDT
R&D
Cell/Gene Tx

No­var­tis dumps AveX­is pro­gram for Rett syn­drome af­ter fail­ing re­peat round of pre­clin­i­cal test­ing

Paul Schloesser

Associate Editor

Say good­bye to AVXS-201.

The Rett syn­drome gene ther­a­py drug made by AveX­is — the biotech that was bought, kept sep­a­rate, then re­named and fi­nal­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

J&J's Darza­lex hits pri­ma­ry end­point in Phase 3 ear­ly-stage mul­ti­ple myelo­ma tri­al

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times